Williams Drake W, Lee Cindy, Kim Terresa, Yagita Hideo, Wu Hongkun, Park Sil, Yang Paul, Liu Honghu, Shi Songtao, Shin Ki-Hyuk, Kang Mo K, Park No-Hee, Kim Reuben H
School of Dentistry, University of California at Los Angeles, Los Angeles, California.
Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
Am J Pathol. 2014 Nov;184(11):3084-93. doi: 10.1016/j.ajpath.2014.07.010. Epub 2014 Aug 28.
Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs after dental-related interventions in patients undergoing treatment with bisphosphonates or denosumab, the neutralizing human anti-receptor activator of NF-κB ligand (RANKL) antibody (Ab). The cause of ONJ by these drugs has been speculated to their direct effects on osteoclasts. However, the extent to which osteoclasts contribute to ONJ pathogenesis remains controversial. Herein, by using a tooth-extraction mouse model with i.v. administration of mouse anti-RANKL Ab or the bisphosphonate zoledronate (ZOL), we show that unresorbed bone due to impaired formation or suppressed functions of osteoclasts, respectively, is associated with ONJ development. After tooth extraction, ONJ-like lesions developed 50% in the anti-RANKL Ab-treated mice and 30% in the ZOL-treated mice. Nonviable and unresorbed bone was found more in anti-RANKL Ab-treated mice compared with mice receiving ZOL. All mice receiving anti-RANKL Ab had an undetectable tartrate-resistant acid phosphatase (TRAP) level in the serum and no TRAP-positive osteoclasts at the extracted sockets, whereas ZOL-treated mice had a decreased TRAP level without altering the numbers of TRAP-positive osteoclasts. Interestingly, the absence of newly formed woven bone in the extracted sockets was evident in ONJ-like lesions from both anti-RANKL Ab- and ZOL-treated mice. Our study suggests that the lack of osteoclasts' bone-resorptive functions by these drugs and suppression of woven bone formation after dental trauma may be associated with ONJ development.
药物性颌骨坏死(ONJ)是一种有害的口腔内病变,常发生于接受双膦酸盐或地诺单抗(一种中和人抗核因子κB受体激活剂配体(RANKL)的抗体(Ab))治疗的患者进行牙科相关干预后。这些药物导致ONJ的原因被推测为它们对破骨细胞的直接作用。然而,破骨细胞在ONJ发病机制中的作用程度仍存在争议。在此,通过使用静脉注射小鼠抗RANKL Ab或双膦酸盐唑来膦酸(ZOL)的拔牙小鼠模型,我们表明,分别由于破骨细胞形成受损或功能受抑制导致的未吸收骨与ONJ的发生有关。拔牙后,抗RANKL Ab治疗的小鼠中有50%出现了类似ONJ的病变,ZOL治疗的小鼠中有30%出现了类似病变。与接受ZOL的小鼠相比,抗RANKL Ab治疗的小鼠中发现更多的无活力且未吸收的骨。所有接受抗RANKL Ab治疗的小鼠血清中抗酒石酸酸性磷酸酶(TRAP)水平检测不到,拔牙窝处也没有TRAP阳性破骨细胞,而ZOL治疗的小鼠TRAP水平降低,但TRAP阳性破骨细胞数量没有改变。有趣的是,抗RANKL Ab和ZOL治疗的小鼠的类似ONJ病变中,拔牙窝处明显缺乏新形成的编织骨。我们的研究表明,这些药物导致破骨细胞骨吸收功能缺乏以及牙科创伤后编织骨形成受抑制可能与ONJ的发生有关。